Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population

被引:61
作者
Mahungu, T. W. [1 ,2 ]
Smith, C. J. [3 ]
Turner, F. [1 ]
Egan, D. [2 ]
Youle, M. [1 ]
Johnson, M. A. [1 ]
Khoo, S. [2 ]
Back, D. J. [2 ]
Owen, A. [2 ]
机构
[1] Royal Free NHS Trust, Dept HIV Med, London NW3 2QG, England
[2] Univ Liverpool, Dept Pharmacol & Therapeut, Sch Biomed Sci, Liverpool L69 3BX, Merseyside, England
[3] Univ Coll Med Sch, Res Dept Infect & Populat Hlth, London, England
关键词
drug disposition; metabolism; pharmacogenetics; pharmacokinetics; INDUCED SKIN RASH; ANTIRETROVIRAL THERAPY; EFAVIRENZ; PHARMACOKINETICS; PHARMACOGENETICS; HIV-1; HEPATOTOXICITY; POLYMORPHISM; ZIDOVUDINE; RESISTANCE;
D O I
10.1111/j.1468-1293.2008.00689.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The aim of the study was to characterize the impact of the cytochrome P450 2B6 (CYP2B6), CYP3A4, CYP3A5 and ATP-binding cassette sub-family B member 1 (ABCB1) polymorphisms on nevirapine plasma concentrations. A total of 104 patients (82% male; 26% non-Caucasian) were genotyped for eight single nucleotide polymorphisms at four loci (CYP2B6, CYP3A4, CYP3A5 and MDR1). Nevirapine plasma concentrations were determined using high-performance liquid chromatography. Non-Caucasian ethnicity [5609 ng/mL (n=27) for non-Caucasians vs. 3771 ng/mL (n=77) for Caucasians; P < 0.0001] and CYP2B6 516G -> T [GG, 3574 ng/mL (n=50); GT, 4634 ng/mL (n=50); TT, 8170 ng/mL (n=4); P-analysis of variance (anova)=0.001] were significantly associated with a higher nevirapine trough concentration (C-trough). The latter association was maintained with both 200 mg twice daily (bid) and 400 mg once daily (qd) dosing [GG, 3527 ng/mL (n=30); GT, 4525 ng/mL (n=32); TT, 7020 ng/mL (n=2); P-anova=0.05 and GG, 3645 ng/mL (n=20); GT, 4861 ng/mL (n=17); TT, 9508 ng/mL (n=2); P-anova=0.01, respectively]. In a multivariable analysis, CYP2B6 516G -> T and non-Caucasian ethnicity remained significant predictors of nevirapine C-trough but CYP2B6 516G -> T homozygosity had the greatest effect (108% higher, 46% higher). No associations were found between nevirapine C-trough and the remaining polymorphisms. In this population, both non-Caucasian ethnicity and carriage of the variant allele of CYP2B6 516G -> T were significant predictors of nevirapine C-trough. The association between CYP2B6 516G -> T and higher plasma nevirapine exposure was maintained at both bid and qd dosing.
引用
收藏
页码:310 / 317
页数:8
相关论文
共 37 条
  • [11] British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008
    Gazzard, B. G.
    [J]. HIV MEDICINE, 2008, 9 (08) : 563 - 608
  • [12] Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVMET 012 randomised trial
    Guay, LA
    Musoke, P
    Fleming, T
    Bagenda, D
    Allen, M
    Nakabiito, C
    Sherman, J
    Bakaki, P
    Ducar, C
    Deseyve, M
    Emel, L
    Mirochnick, M
    Fowler, MG
    Mofenson, L
    Miotti, P
    Dransfield, K
    Bray, D
    Mmiro, F
    Jackson, JB
    [J]. LANCET, 1999, 354 (9181) : 795 - 802
  • [13] HAAS D, 2008, 15 C RETR OPP INF BO
  • [14] Pharmacogenetics of nevirapine-associated hepatotoxicity: An adult AIDS clinical trials group collaboration
    Haas, David W.
    Bartlett, John A.
    Andersen, Janet W.
    Sanne, Ian
    Wilkinson, Grant R.
    Hinkle, John
    Rousseau, Franck
    Ingram, Christiana D.
    Shaw, Audrey
    Lederman, Michael M.
    Kim, Richard B.
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 43 (06) : 783 - 786
  • [15] Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir:: An adult AIDS clinical trials group study
    Haas, DW
    Smeaton, LM
    Shafer, RW
    Robbins, GK
    Morse, GD
    Labbé, L
    Wilkinson, GR
    Clifford, DB
    D'Aquila, RT
    De Gruttola, V
    Pollard, RB
    Merigan, TC
    Hirsch, MS
    George, AL
    Donahue, JP
    Kim, RB
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (11) : 1931 - 1942
  • [16] Haas DW, 2004, AIDS, V18, P2391
  • [17] Case-control exploration of relationships between early rash or liver toxicity and plasma concentrations of Nevirapine and primary metabolites
    Hall, David B.
    MacGregor, Thomas R.
    [J]. HIV CLINICAL TRIALS, 2007, 8 (06): : 391 - 399
  • [18] Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo
    He, P
    Court, MH
    Greenblatt, DJ
    von Moltke, LL
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (05) : 373 - 387
  • [19] Kappelhoff BS, 2005, ANTIVIR THER, V10, P489
  • [20] Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans - Prevalence and associated factors
    Kiguba, Ronald
    Byakika-Tusiime, Jayne
    Karamagi, Charles
    Ssali, Francis
    Mugyenyi, Peter
    Katabira, Elly
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 45 (02) : 218 - 223